Drug Profile
Research programme: sustained release therapeutics - Labopharm/Meda Pharmaceuticals
Alternative Names: DDS-2001Latest Information Update: 10 Oct 2011
Price :
$50
*
At a glance
- Originator Labopharm
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 29 Nov 2004 This programme is still in active development
- 08 Aug 2003 Labopharm has completed feasibility and formulation studies for DDS 2001
- 11 Jul 2002 Preclinical trials in Undefined in Canada (unspecified route)